Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Genome Sciences Changes Name to Reflect Rx Focus

NEW YORK (GenomeWeb News) – Oxford Genome Sciences today said that it has changed its name to Oxford BioTherapeutics.
 
The Oxford, UK-based firm said the name change comes as it focuses its efforts on the development of its pipeline of antibody-based cancer therapeutics. The firm also has a collaboration with diagnostics firm Biosite to develop companion diagnostics for its cancer therapeutics.
 
Oxford BioTherapeutics CEO Christian Rohlff said in a statement that the new name “truly embodies the core strategic focus of the company on the development of successful antibody-based drugs for cancer, with integrated diagnostics.”
 
OGS was formed in 2004 by the proteomics products team from Oxford GlycoSciences, which closed that part of its business after its acquisition by Celltech in late 2003. OGS’ primary focus had been on helping pharmaceutical companies discover biomarkers and protein targets and to validate biomarkers and drug targets.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.